BPTS News and Press, Biophytis SA From 02/27/23

Biophytis to present the early access application in France at a pre-filing meeting in March with the HAS Biophytis plans to file the application shortly after with the objective of obtaining early access authorization in France in the second quarter of 2023 Biophytis is pursuing in par...

Delegation to the Board of Directors to reduce the nominal value Regrouping of the company's shares Renewal of Authorizations granted at the June 2022 AGM PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / February 23, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Biophytis (NASDAQ: BPTS ) stock is taking off on Thursday after the company released results from a Phase 2/3 clinical trial . That clinical trial covers the use of Sarconeos as a treatment f...

COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe and the USA PARIS, FRANCE / CAMBRIDGE, MA / AC...

Biophytis press release ( NASDAQ: BPTS ): 1H GAAP EPS of -€0.08. Cash and cash equivalents on the 30th of June 2022 amounted to €19.7M. The Company considers that this amount, together with the credit lines in place, is sufficient to cover the Company's cash requ...

Cash and cash equivalents: €19.7m as of June 30, 2022 Net loss down 8% at €12.4m for first half of 2022 Publication of restated financial results as of December 31st, 2021 PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / January 31, 2023 / Biophytis SA (NasdaqCM:BPTS, Eu...

The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021 PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 19, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology com...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 12, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / January 5, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,...

Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of repiratory failure, Biophytis management is inviting all of Biophytis' stakeholders to an onl...